March 03, 2015 5:44 PM ET

Company Overview of University of California-San Francisco

Company Overview

University of California-San Francisco is an education institution offering programs such as biological, biomedical, pharmaceutical, nursing, social and behavioral sciences, dentistry, medicine, and nursing and pharmacy. The schools of the university include Continuing Medical Education, School of Dentistry, School of Medicine, School of Nursing, and School of Pharmacy. University of California- San Francisco was established in 1897 and is based in San Francisco, California. The university has endowment assets worth $873 million.

San Francisco, CA 94143

United States

Founded in 2007

Phone:

415-476-9000

Fax:

415-476-3428

Key Executives for University of California-San Francisco

Chancellor
Age: 57
Professor of Tumor Biology and Cancer Research, Department of Microbiology and Immunology
Age: 64
Executive Director of News
Executive Director of Global Health Sciences
Professor
Age: 64
Compensation as of Fiscal Year 2014.

University of California-San Francisco Key Developments

BioMotiv, University of California San Francisco and University of Washington Announces Formation of Optikira

BioMotiv, the University of California San Francisco and University of Washington are announcing the formation of OptiKira, a platform company that will develop small molecule therapeutics that prevent cell death in pathologies caused by misfolded or unfolded proteins. OptiKira is based on intellectual property exclusively licensed from UCSF and University of Washington. The project was initiated at UCSF and the University of Washington by scientific founders Scott Oakes, MD, Associate Professor of Pathology at UCSF, Feroz Papa, MD, PhD, Associate Professor of Medicine at UCSF, Bradley Backes, PhD, Associate Professor of Medicine at UCSF, and Dustin Maly, PhD, Associate Professor in Chemistry at University of Washington. Dr. Oakes and Dr. Papa are members of the first class of Harrington Scholar-Innovators. Extensive research by the Founders has helped define the biological pathway leading to progressive cell death which characterizes diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis (ALS). They have found that the Unfolded Protein Response (UPR), a mechanism by which the cell deals with functionally abnormal proteins, has an important housekeeping role in cell metabolism. However when overloaded, the 'terminal UPR' results in the accumulation of excessive unfolded proteins and cellular death. The team has synthesized inhibitors of IRE1a to prevent the activation of the terminal UPR, while not disrupting the housekeeping role of the enzyme. They have demonstrated that inhibitors of IRE1a, which they have named kinase-inhibiting RNase attenuators (KIRAs), protect cells from degeneration in preclinical models of retinitis pigmentosa and diabetes.

University of California San Diego and University of California San Francisco Launch New Cancer Cell Mapping Initiative

Researchers from the University of California, San Diego School of Medicine and University of California, San Francisco, with support from a diverse team of collaborators, have launched an ambitious new project - dubbed the Cancer Cell Map Initiative or CCMI - to determine how all of the components of a cancer cell interact. In recent years, progress in genome sequencing has made it possible to decipher hundreds of mutations found in a patient's tumor. But in only a few cases do scientists understand how these mutations give rise to cancer or indicate what treatments to pursue. More puzzling still, the mutations found in each patient are almost always different - even though they can lead to the same type of cancer. It has long been thought that, while these mutations are unique to individuals, they hijack the same hallmark cancer pathways or genetic circuits. To interpret genomic data, researchers say the complete wiring diagram of the cell is needed, one that details all of the connections between normal and mutated genes and proteins. The CCMI will provide key infrastructure for the recently announced alliance between UC San Diego Health Sciences and San Diego-based Human Longevity Inc., which plans to generate thousands of tumor genomes from UC San Diego cancer patients. It will also leverage resources and information from the National Cancer Institute (NCI), including large databases of cancer genomes and pathways that are being developed in collaboration with the San Diego Supercomputer Center and UC Santa Cruz.

UC San Francisco and OncoSec Medical Collaborate to Evaluate Investigational Combination of ImmunoPulse and Anti-PD-1 Treatment

OncoSec Medical Inc. has entered a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. Recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents. Interleukin-12 (IL-12) is an inflammatory cytokine believed to be a master regulator of the immune system, promoting up-regulation of both the innate and adaptive immune responses. More specifically, IL-12 stimulates the production of another cytokine, interferon gamma (IFN-), which results in the stimulation of antigen processing and presentation machinery, leading to increased TILs and anti-tumor cytotoxic T-cell (CTL) activity. ImmunoPulse, an investigational intratumoral immunotherapy, uses plasmid DNA that encodes for IL-12 and delivers it directly into the tumor using a proprietary electroporation device. Preclinical and clinical data suggest that local delivery and expression of IL-12 with ImmunoPulse promotes tumor immunogenicity and increases TILs without the toxicities associated with systemic IL-12 administration. Recent interim data from OncoSec's ongoing Phase II study have demonstrated that plasmid IL-12 electroporation treatment increases IFN- production and increased expression of genes related to antigen processing and presentation, including the expression of PD-L1.

Similar Private Companies By Industry

Company Name Region
Kansas Masonic Home United States
Goldstein Capital Corp United States
Hildalgo Trading Company United States
DataCede LLC United States
Jamestown Allenco, Inc United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact University of California-San Francisco, please visit www.ucsf.edu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.